NHWA(002262.SZ)

Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin fumarate injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, olanzapine tablets, midazolam hydrochloride oral solution, clonazepam injection, lacosamide injection, micuronium injection, pregabalin capsules, vortioxetine hydrobromide tablets, tapentadone hydrochloride tablets, and oxycodone hydrochloride extended-release tablets. The company was founded in 1978 and is headquartered in Xuzhou, China.